|
1
|
Grönberg H: Prostate cancer epidemiology.
Lancet. 361:859–864. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Diamandis EP: Prostate-specific antigen:
Its usefulness in clinical medicine. Trends Endocrinol Metab.
9:310–316. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Abdollah F, Karnes RJ, Suardi N, et al:
Predicting survival of patients with node-positive prostate cancer
following multimodal treatment. Eur Urol. 65:554–562. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Saraon P, Jarvi K and Diamandis EP:
Molecular alterations during progression of prostate cancer to
androgen independence. Clin Chem. 57:1366–1375. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Freedland SJ, Humphreys EB, Mangold LA,
Eisenberger M, Dorey FJ, Walsh PC and Partin AW: Risk of prostate
cancer-specific mortality following biochemical recurrence after
radical prostatectomy. JAMA. 294:433–439. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
D'Amico AV, Whittington R, Malkowicz SB,
Wu YH, Chen M, Art M, Tomaszewski JE and Wein A: Combination of the
preoperative PSA level, biopsy gleason score, percentage of
positive biopsies, and MRI T-stage to predict early PSA failure in
men with clinically localized prostate cancer. Urology. 55:572–577.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tsivian M, Sun L, Mouraviev V, Madden JF,
Mayes JM, Moul JW and Polascik TJ: Changes in gleason score grading
and their effect in predicting outcome after radical prostatectomy.
Urology. 74:1090–1093. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Budäus L, Isbarn H, Eichelberg C,
Lughezzani G, Sun M, Perrotte P, Chun FK, Salomon G, Steuber T,
Köllermann J, et al: Biochemical recurrence after radical
prostatectomy: Multiplicative interaction between surgical margin
status and pathological stage. J Urol. 184:1341–1346. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Miyake H, Muramaki M, Kurahashi T, et al:
Expression of potential molecular markers in prostate cancer:
Correlation with clinicopathological outcomes in patients
undergoing radical prostatectomy. Urol Oncol. 28:145–151. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thirumoorthy N, Shyam Sunder A,
Manisenthil Kumar K, Senthil Kumar M, Ganesh G and Chatterjee M: A
review of metallothionein isoforms and their role in
pathophysiology. World J Surg Oncol. 9:542011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Theocharis SE, Margeli AP, Klijanienko JT
and Kouraklis GP: Metallothionein expression in human neoplasia.
Histopathology. 45:103–118. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Putzke AP, Ventura AP, Bailey AM, et al:
Metastatic progression of prostate cancer and e-cadherin:
Regulation by Zeb1 and Src family kinases. Am J Pathol.
179:400–410. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nguyen DP, Li J and Tewari AK:
Inflammation and prostate cancer: The role of interleukin 6 (IL-6).
BJU Int. 113:986–992. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Balk SP and Knudsen KE: AR, the cell cycle
and prostate cancer. Nucl Recept Signal. 6:e0012008.PubMed/NCBI
|
|
16
|
Azevedo A, Cunha V, Teixeira AL and
Medeiros R: IL-6/IL-6R as a potential key signaling pathway in
prostate cancer development. World J Clin Oncol. 2:384–396. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moul JW: Angiogenesis, p53, bcl-2 and
Ki-67 in the progression of prostate cancer after radical
prostatectomy. Eur Urol. 35:399–407. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mohler JL: The 2010 NCCN clinical practice
guidelines in oncology on prostate cancer. J Natl Compr Canc Netw.
8:1452010.PubMed/NCBI
|
|
19
|
Yu H, Diamandis EP, Wong PY, Nam R and
Trachtenberg J: Detection of prostate cancer relapse with prostate
specific antigen monitoring at levels of 0.001 to 0.1 microG/L. J
Urol. 157:913–918. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zellweger T, Ninck C, Mirlacher M,
Annefeld M, Glass AG, Gasser TC, Mihatsch MJ, Gelmann EP and
Bubendorf L: Tissue microarray analysis reveals prognostic
significance of syndecan-1 expression in prostate cancer. Prostate.
55:20–29. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
TsurumakiSato Y, Fukuhara H, Suzuki M,
Fujimura T, Nakagawa T, Nishimatsu H, Kume H, Morikawa T, Fukayama
M and Homma Y: Long-term results of radical prostatectomy with
immediate adjuvant androgen deprivation therapy for pT3N0 prostate
cancer. BMC Urol. 14:132014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Murphy AM, Berkman DS, Desai M, Benson MC,
McKiernan JM and Badani KK: The number of negative pelvic lymph
nodes removed does not affect the risk of biochemical failure after
radical prostatectomy. BJU Int. 105:176–179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lim D, Jocelyn KM, Yip GW and Bay BH:
Silencing the metallothionein-2A gene inhibits cell cycle
progression from G1-to S-phase involving ATM and cdc25A signaling
in breast cancer cells. Cancer lett. 276:109–117. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schraml P, Bucher C, Bissig H, Nocito A,
Haas P, Wilber K, Seelig S, Kononen J, Mihatsch MJ, Dirnhofer S, et
al: Cyclin E overexpression and amplification in human tumours. J
Pathol. 200:375–382. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rao PS, Jaqqi M, Smith DJ, Hemstreet GP
and Balaji KC: Metallothionein 2A interacts with the kinase domain
of PKCmu in prostate cancer. Biochem Biophys Res Commun.
310:1032–1038. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Garrett SH, Sens MA, Shukla D, Flores L,
Somji S, Todd JH and Sens DA: Metallothionein isoform 1 and 2 gene
expression in the human prostate: Downregulation of MT-1X in
advanced prostate cancer. Prostate. 43:125–135. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gumulec J, Raudenska M, Adam V, Kizek R
and Masarik M: Metallothionein-immunohistochemical cancer
biomarker: A meta-analysis. PLoS One. 9:e853462014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhong WD, Liang YX, Lin SX, Li L, He HC,
Bi XC, Han ZD, Dai QS, Ye YK, Chen QB, et al: Expression of CD147
is associated with prostate cancer progression. Int J Cancer.
130:300–308. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jaggi M, Johansson SL, Baker JJ, Smith LM,
Galich A and Balaji KC: Aberrant expression of E-cadherin and
beta-catenin in human prostate cancer. Urol Oncol. 23:402–406.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gravdal K, Halvorsen OJ, Haukaas SA and
Akslen LA: A switch from E-cadherin to N-cadherin expression
indicates epithelial to mesenchymal transition and is of strong and
independent importance for the progress of prostate cancer. Clin
Cancer Res. 13:7003–7011. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu TT, Hsu YS, Wang JS, Lee YH and Huang
JK: The role of p53, bcl-2 and E-cadherin expression in predicting
biochemical relapse for organ confined prostate cancer in Taiwan. J
Urol. 170:78–81. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nariculam J, Freeman A, Bott S, Munson P,
Cable N, BrookmanAmissah N, Williamson M, Kirby RS, Masters J and
Feneley M: Utility of tissue microarrays for profiling prognostic
biomarkers in clinically localized prostate cancer: The expression
of Bcl-2, E-cadherin, Ki-67 and p53 as predictors of biochemical
failure after radical prostatectomy with nested control for
clinical and pathological risk factors. Asian J Androl. 11:109–118.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ishiguro H, Akimoto K, Nagashima Y, Kagawa
E, Sasaki T, Sano JY, Takagawa R, Fujinami K, Sasaki K, Aoki I, et
al: Coexpression of aPKCλ/ι and IL-6 in prostate cancer tissue
correlates with biochemical recurrence. Cancer Sci. 102:1576–1581.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhong W, Peng J, He H, Wu D, Han Z, Bi X
and Dai Q: Ki-67 and PCNA expression in prostate cancer and benign
prostatic hyperplasia. Clin Invest Med. 31:E8–E15. 2008.PubMed/NCBI
|
